BBNX vs BFLY
BBNX: Beta Bionics is a medical device company developing automated insulin delivery systems to simplify diabetes management. BFLY: Butterfly Network is transforming medical imaging with its semiconductor-based, handheld point-of-care ultrasound technology that brings clinical-grade scanning to the palm of the hand.
Side-by-side fundamentals
| Metric | BBNX | BFLY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $16.31 | $6.61 | |
| Market cap as of 2026-07-23 | $780M | $1.8B | |
| PEG as of 2026-07-23 | n/a | -28.19 | |
| Net margin as of 2026-07-23 | -60.3% | -73.7% | BBNX higher |
| Gross margin as of 2026-07-23 | +57.1% | +49.2% | BBNX higher |
| Operating margin as of 2026-07-23 | -70.1% | -79.5% | BBNX higher |
| ROE as of 2026-07-23 | -23.0% | -36.8% | BBNX higher |
| ROA as of 2026-07-23 | -20.5% | -25.6% | BBNX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +56.6% | +20.2% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +10.0% | BBNX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.50 | 2.10 | |
| 1-year return as of 2026-07-22 close | +23.2% | +262.8% | BFLY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.